These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34763645)

  • 1. [Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)].
    Proshkina AA; Tsareva NA; Nekludova GV; Avdeev SN
    Kardiologiia; 2021 Oct; 61(10):104-107. PubMed ID: 34763645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
    Furukawa A; Tamura Y; Iwahori H; Goto M; Ohashi N; Okabe T; Kawamura A
    BMC Pulm Med; 2017 Oct; 17(1):135. PubMed ID: 29073911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
    Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
    J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on pharmacotherapy for pulmonary hypertension.
    Prior DL; Adams H; Williams TJ
    Med J Aust; 2016 Sep; 205(6):271-6. PubMed ID: 27627939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension.
    Hu X; Yuan P; Chen J; Wang S; Zhao H; Wei Y; Fu J; Chen F; Ruan H; Zhang W; Zhou Y; Wang Q; Xu X; Feng K; Guo J; Gong S; Zhang R; Zhao Q; Wang L
    Clin Cardiol; 2024 Feb; 47(2):e24245. PubMed ID: 38402556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry).
    McLaughlin V; Farber HW; Highland KB; Hemnes AR; Chakinala MM; Chin KM; Han M; Cho M; Tobore T; Rahman M; Kim NH
    J Heart Lung Transplant; 2024 Feb; 43(2):272-283. PubMed ID: 37778526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　- Protocol of a Multicenter Randomized Control Trial.
    Akagi S; Dohi Y; Ishikawa K; Kubota K; Horimoto K; Yagi S; Hirata T; Yamamoto E; Ito H; Nakamura K
    Circ Rep; 2021 Jan; 3(2):105-109. PubMed ID: 33693297
    [No Abstract]   [Full Text] [Related]  

  • 10. Selexipag for the treatment of pulmonary arterial hypertension.
    Genecand L; Wacker J; Beghetti M; Lador F
    Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.
    Alexandre A; Furtado I; Carvalho L; Gonçalves F; Melo A; Alves J; Santos M; Reis A
    ESC Heart Fail; 2023 Aug; 10(4):2722-2727. PubMed ID: 37336527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling.
    Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE
    Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety concerns regarding selexipag in pulmonary arterial hypertension.
    Greene RA
    Am J Health Syst Pharm; 2018 Apr; 75(7):419-420. PubMed ID: 29572306
    [No Abstract]   [Full Text] [Related]  

  • 15. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
    Hardin EA; Chin KM
    Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline history of patients using selexipag for pulmonary arterial hypertension.
    Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
    Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
    Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.
    Takatsuki S; Nakayama T; Shimizu Y; Kawai R; Matsuura H
    Cardiol Young; 2023 Feb; 33(2):196-200. PubMed ID: 35383553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selexipag for the treatment of pulmonary arterial hypertension.
    Noel ZR; Kido K; Macaulay TE
    Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of selexipag for the treatment of pulmonary hypertension.
    Panagiotidou E; Boutou A; Pitsiou G
    Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.